ALP Bio AG, a Schlieren-based biotech, has closed a CHF 1.75M pre-seed round led by Munich-based 42CAP, with participation from Venture Kick and angel investors. The funding will accelerate ALP Bio's platform, which combines human immune organoid biology with generative AI to help antibody developers identify and reduce immunogenicity risk earlier in drug development.

arcoris bio, an innovative biotech company, and Betta Scientific have entered a strategic collaboration to accelerate global market access of arcoris bio’s multiplex immunofluorescence kits. Leveraging Betta Scientific’s expertise in business-to-consumer strategy and distribution network development, the partnership will expand presence across Europe, APAC, and the Americas.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced the expansion of its commercial activities in the APAC area with the opening of a new office in Tokyo, Japan. This strategic move marks a significant milestone in the company’s global growth and further strengthens its ability to serve biotech and

New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model